Kennedy Capital Management, Inc. Protagonist Therapeutics, Inc Transaction History

Kennedy Capital Management, Inc.

$3.99 Billion
Q1 2025

A detailed history of Kennedy Capital Management, Inc. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Kennedy Capital Management, Inc. holds 137,504 shares of PTGX stock, worth $6.09 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares

137,504

Previous 321,526 57.23%

Holding current value

$6.09 Million

Previous $12.4 Million 46.42%

% of portfolio

0.17%

Previous 0.29%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$35.09 - $59.76 $6.46 Million - $11 Million	-184,022 Reduced 57.23%	137,504 $6.65 Million
Q4 2024 Feb 13, 2025	BUY	$38.51 - $48.43 $2.1 Million - $2.64 Million	54,493 Added 20.41%	321,526 $12.4 Million
Q3 2024 Nov 14, 2024	SELL	$33.72 - $47.33 $777,212 - $1.09 Million	-23,049 Reduced 7.95%	267,033 $12 Million
Q2 2024 Aug 14, 2024	SELL	$24.66 - $34.8 $196,934 - $277,912	-7,986 Reduced 2.68%	290,082 $10.1 Million
Q1 2024 May 15, 2024	SELL	$21.79 - $32.15 $146,472 - $216,112	-6,722 Reduced 2.21%	298,068 $8.62 Million
Q4 2023 Feb 14, 2024	SELL	$14.05 - $23.44 $207,153 - $345,599	-14,744 Reduced 4.61%	304,790 $6.99 Million
Q3 2023 Nov 14, 2023	SELL	$16.68 - $23.66 $1.4 Million - $1.99 Million	-84,114 Reduced 20.84%	319,534 $5.33 Million
Q2 2023 Aug 14, 2023	BUY	$18.02 - $29.36 $1.3 Million - $2.12 Million	72,366 Added 21.84%	403,648 $11.1 Million
Q1 2023 May 15, 2023	SELL	$10.78 - $25.38 $203,213 - $478,438	-18,851 Reduced 5.38%	331,282 $7.62 Million
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $1.85 Million - $2.8 Million	251,046 Added 253.36%	350,133 $3.82 Million
Q3 2022 Nov 14, 2022	SELL	$7.86 - $11.71 $699 - $1,042	-89 Reduced 0.09%	99,087 $835,000
Q2 2022 Aug 10, 2022	BUY	$7.06 - $25.52 $13,491 - $48,768	1,911 Added 1.96%	99,176 $784,000
Q1 2022 May 16, 2022	SELL	$23.34 - $36.08 $189,730 - $293,294	-8,129 Reduced 7.71%	97,265 $2.3 Million
Q4 2021 Feb 14, 2022	SELL	$17.63 - $37.1 $121,135 - $254,914	-6,871 Reduced 6.12%	105,394 $3.6 Million
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $522,118 - $2 Million	40,318 Added 56.04%	112,265 $1.99 Million
Q2 2021 Aug 16, 2021	SELL	$25.57 - $44.88 $91,310 - $160,266	-3,571 Reduced 4.73%	71,947 $3.23 Million
Q1 2021 May 14, 2021	BUY	$19.02 - $31.15 $1.44 Million - $2.35 Million	75,518 New	75,518 $1.96 Million

Others Institutions Holding PTGX

# of Institutions

271

Shares Held

56.4M

Call Options Held

226K

Put Options Held

218K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.17B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Kennedy Capital Management, Inc. with notifications on news.

Account

Kennedy Capital Management, Inc. Protagonist Therapeutics, Inc Transaction History